NYSE:ABT

Abbott Starts VOYAGER Trial for Software-Guided Encantor TAVI System

Abbott (NYSE: ABT) initiated the VOYAGER CE clinical trial evaluating its investigational Encantor balloon-expandable transcatheter aortic valve implantation system for patients with symptomatic severe aortic stenosis.

The prospective, single-arm study will enroll up to 300 patients in Europe and Australia and is intended to support regulatory approval in those markets. Encantor uses software-guided deployment to tailor valve expansion to individual patient anatomy, with the goal of improving implantation precision and procedural consistency.

The platform is designed to complement Abbott’s existing Navitor self-expanding TAVI system, giving physicians a balloon-expandable alternative within the company’s structural heart portfolio. Abbott said early feasibility data supported advancement into the VOYAGER CE trial, while a U.S. pivotal study is planned in the coming months.

The trial represents an important development milestone for Abbott’s structural heart business, but Encantor remains investigational and is not yet approved for commercial use. Successful clinical and regulatory progress could broaden Abbott’s competitive position in the transcatheter heart-valve market over the longer term.
Post Image
Abbott Wins FDA Approval and CE Mark for UltiSynq Defibrillation Lead

Abbott (NYSE: ABT) received both U.S. FDA approval and CE Mark for UltiSynq, a new implantable cardioverter-defibrillator lead designed to deliver conduction system pacing and defibrillation therapy through the heart’s natural electrical pathway.

UltiSynq is designed for implantation in the left bundle branch area, allowing physicians to combine physiologic pacing with ICD or CRT-D protection in a single lead. The device previously received FDA Breakthrough Device designation.

Approval was supported by the ASCEND CSP IDE trial. Among 205 implant attempts, implantation was successful in 98.5% of patients, while 86% of successfully implanted patients achieved confirmed or likely left bundle branch pacing.

The study also reported a 97.5% major complication-free rate at three months. Among 120 patients who underwent defibrillation testing, successful defibrillation was achieved in 100% of cases without requiring lead repositioning.

Abbott said UltiSynq’s short shock coil and true bipolar sensing are designed to improve positioning precision and reduce susceptibility to P-wave oversensing, which can potentially trigger inappropriate therapy.

The approvals expand Abbott’s cardiac rhythm management portfolio and give physicians a new option for patients who require both defibrillation protection and conduction system pacing, an approach aimed at producing a more coordinated and physiologic heartbeat.
Post Image
Abbott Launches Pivotal Trial for Cephea Mitral Valve Replacement System

Abbott (NYSE: ABT) has initiated the CROWN-MV pivotal trial evaluating its investigational Cephea Mitral Valve System, a minimally invasive transcatheter replacement therapy for patients with symptomatic mitral valve disease who are not candidates for surgery or transcatheter repair.

The global prospective study will enroll up to 585 patients across the U.S., Canada and Europe. It will evaluate patients with moderate-to-severe or severe mitral regurgitation, as well as mitral valve dysfunction associated with mitral annular calcification.

Cephea is delivered through a catheter inserted through a vein in the leg and guided to the heart, where a bioprosthetic valve is implanted inside the diseased mitral valve. The system is designed to expand Abbott’s existing mitral valve portfolio, which already includes MitraClip and the Tendyne transcatheter mitral valve replacement system.

The pivotal trial follows encouraging early clinical development. Abbott said 30-day results from an early feasibility study using its third-generation Cephea delivery system will be presented at the TCT 2026 scientific meeting, with data expected to address mitral regurgitation reduction and quality-of-life outcomes.

The trial represents an important regulatory and commercial development milestone for Abbott’s structural heart business. If successful, Cephea could broaden treatment options for high-risk patients with complex mitral valve anatomy who currently have limited alternatives.

Abbott also plans to present additional TCT 2026 data across several cardiovascular platforms, including Amulet 360, SonicForce, Encantor, Amplatzer Paraclose and Navitor, reinforcing the breadth of its structural heart and cardiovascular pipeline.
Post Image
Abbott Launches Ensure Max Protein 3-in-1 Muscle Support With Protein, Creatine and HMB

Abbott (NYSE: ABT) launched Ensure Max Protein 3-in-1 Muscle Support, a new powdered nutrition product that combines protein, creatine monohydrate and HMB in a single daily serving.

Each serving provides 30 grams of high-quality protein, 5 grams of creatine monohydrate and 3 grams of calcium HMB. Abbott said the formula is designed to support muscle building, exercise recovery and muscle preservation, targeting consumers who would otherwise combine several separate supplements.

The product reflects a broader consumer shift toward strength, active aging and muscle health. Abbott noted that ingredients such as creatine are moving beyond traditional sports nutrition as more adults focus on maintaining strength and physical function over time.

Ensure Max Protein 3-in-1 Muscle Support is available in chocolate and vanilla flavors and is being sold through major U.S. retailers including Walmart and Amazon. The product comes in a 28-ounce powder format, with a suggested daily serving of two scoops.

Abbott said the formulation is also NSF Contents Certified, providing third-party verification around ingredient quality and label accuracy.

The launch expands Abbott’s nutrition portfolio into the growing mainstream muscle-health category, combining elements of traditional protein supplementation with creatine and HMB in a single product aimed at active adults.
Post Image
Abbott (NYSE: ABT) said the U.S. Food and Drug Administration approved new capabilities for its CardioMEMS HF System, allowing patients to view pulmonary artery pressure readings and receive personalized treatment updates through the CardioGuide HF App.

The update gives U.S. CardioMEMS patients direct access to their pulmonary artery pressure trends on smartphones. Rising pressure can indicate worsening heart failure weeks before symptoms such as shortness of breath or swelling appear, giving clinicians an opportunity to adjust treatment earlier.

Abbott also received approval for Dynamic Treatment Plan, a feature that lets care teams send individualized medication adjustment instructions to patients through the app based on changes in pulmonary artery pressure.

The company said the new tools are designed to strengthen remote heart failure management by keeping patients and clinicians more closely connected between office visits.

Abbott plans to make the CardioGuide HF App and Dynamic Treatment Plan available later in 2026.
Post Image
Abbott Launches SimpleScreen CRC Blood Test for Colorectal Cancer Screening

Abbott announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.

Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC expands the company’s colorectal cancer screening portfolio alongside Cologuard Plus. The blood-based test is intended as an option for eligible patients who decline or do not complete preferred stool-based or visual screening methods.

SimpleScreen CRC uses circulating cell-free DNA in blood to detect signals associated with colorectal cancer. In the PREEMPT CRC validation study involving more than 48,000 adults, the test demonstrated 81.1% overall sensitivity for colorectal cancer, including 63.5% sensitivity for Stage I disease. It also showed 90.4% specificity for advanced colorectal neoplasia.

Abbott said the test is covered by Medicare, with no out-of-pocket costs for eligible patients with Medicare Part B. Patients can complete the blood draw through participating laboratories or mobile phlebotomy services.

The company is also extending its patient navigation infrastructure to SimpleScreen CRC, including blood-draw coordination, reminders, insurance assistance, bilingual support and follow-up services.

Abbott is positioning the launch as a way to expand colorectal cancer screening participation by offering an additional noninvasive option for patients who might otherwise remain unscreened.
Post Image
Abbott Highlights Lower Mortality and Hospitalization Risk With Libre CGM in Type 2 Diabetes

Abbott reported new real-world data linking continuous glucose monitoring, including its Libre technology, with lower mortality and fewer cardiovascular complications among adults with Type 2 diabetes using basal insulin.

In a U.S. study of nearly 28,000 adults, CGM use was associated with a 45% lower risk of death at 12 months and a 36% lower risk at 24 months compared with non-users. Researchers also found fewer cardiovascular-related complications among CGM users.

A separate French observational study involving more than 253,000 people with Type 2 diabetes found that acute diabetes-event hospitalizations fell 47% among basal-insulin users after starting Libre. The reduction was 56% among people using multiple daily insulin injections and 81% among those using non-insulin therapies.

Abbott is also highlighting new FreeDM2 trial analyses showing that people using Libre 3 experienced improvements in time in range within the first 24 hours, with benefits sustained over time.

The company is also showcasing Libre Assist, an AI-powered feature that predicts how food choices may affect glucose levels and provides personalized meal guidance.

The findings strengthen Abbott’s case for broader CGM use beyond intensive insulin therapy, although the mortality results are observational and show association rather than proof of causation.
Post Image
Abbott and Berry Street Partner to Expand Personalized Nutrition Support Using Lingo CGM

Abbott and Berry Street announced an exclusive partnership that combines Abbott’s Lingo continuous glucose monitor with virtual support from registered dietitians to help consumers make more personalized nutrition and lifestyle decisions.

Lingo is an over-the-counter CGM designed for adults who are not using insulin. It shows how factors such as food, exercise, sleep and stress affect glucose levels, while Berry Street dietitians will use that data to provide individualized nutrition guidance.

Through the partnership, users can access dietitians trained on Lingo and continuous glucose monitoring, receive recommendations based on their glucose patterns and meet virtually through one-on-one appointments. Berry Street is in-network with more than 1,250 health plans, and the company said 96% of clients pay no out-of-pocket cost, depending on their insurance coverage.

Berry Street users will also be able to purchase Lingo at a 15% discount on four-week plans, while dietitians can view patients’ glucose data to provide more targeted coaching.

The partnership expands Abbott’s push into consumer metabolic health by combining real-time biosensor data with human nutrition expertise, rather than positioning glucose tracking as a standalone wellness tool.
Post Image
Abbott Expands Volt Pulsed Field Ablation System to Canada

Abbott (NYSE: ABT) announced the first commercial use of its Volt Pulsed Field Ablation System in Canada, marking an expansion of the company’s next-generation technology for treating atrial fibrillation. The first Canadian procedures were performed at McGill University Health Centre in Montreal.

Volt uses high-energy electrical pulses to target heart tissue responsible for abnormal rhythms. Its balloon-in-basket catheter is designed to improve tissue contact and deliver precise energy with fewer therapy applications, while integration with Abbott’s EnSite X platform provides 3D cardiac mapping and reduces catheter exchanges.

The system can also support conscious sedation instead of general anesthesia and is designed to reduce radiation exposure during procedures, potentially improving procedural efficiency and recovery.

Health Canada authorized Volt in April 2026 following clinical evidence including Abbott’s 392-patient VOLT-AF IDE study. The system is also approved and available in the U.S., Europe and Australia, expanding Abbott’s position in the growing cardiac electrophysiology and pulsed-field ablation market.
Post Image
Abbott Reaches $385 Million Settlement With DOJ Over 2022 Infant Formula Recall

Abbott said it reached an agreement to resolve U.S. Department of Justice and related state claims stemming from the company’s manufacturing operations and 2022 recall of powdered infant formula from its Sturgis, Michigan facility.

Under the agreement, Abbott will pay a total of $385 million to resolve the claims. The company emphasized that the settlement does not constitute a finding of fault or liability and said the government had previously closed its criminal investigation into the matter.

Abbott also said no unopened, distributed infant formula involved in the matter ever tested positive for Cronobacter sakazakii. According to the company, FDA testing of unopened products from the homes of infants investigated during the recall was negative, while the CDC later concluded there was no definitive link between the Sturgis facility and the clinical cases under investigation.

The settlement provides greater legal clarity around a major issue that has followed Abbott since the 2022 recall, which disrupted U.S. infant-formula supplies and drew significant regulatory scrutiny. The $385 million payment represents a financial cost for Abbott, but resolving the litigation removes an important source of uncertainty surrounding its nutrition business.
Video Thumbnail
01-22-26WS News